2024
A retrospective analysis of factors associated with deep contraceptive implant removals compared to superficial removals
Kendall P, Bresnitz W, Huang J, Sheeder J, Lazorwitz A. A retrospective analysis of factors associated with deep contraceptive implant removals compared to superficial removals. Contraception 2024, 137: 110486. PMID: 38754757, DOI: 10.1016/j.contraception.2024.110486.Peer-Reviewed Original ResearchContraceptive implant removalLower body mass indexBody mass indexImplant removalSuperficial removalWeight gainAssociated with younger ageRetrospective cohort studyMann-Whitney U testMultivariate logistic regressionAssociated with increased oddsFactors associated with increased likelihoodHealth record reviewContraceptive implantsImplant exchangeFischer's exactElectronic health record reviewImplant useComparing PatientsRetrospective analysisMass indexCohort studyPatient characteristicsRemoval groupInserting contraceptive implants
2023
Survival outcomes and toxicity in older adults with metastatic castration-resistant prostate cancer (mCRPC) treated with androgen receptor targeted (ART) therapies.
Mellgard G, Chakrani Z, Mccroskery S, Saffran N, Taylor N, Liaw B, Galsky M, Oh W, Tsao K, Patel V. Survival outcomes and toxicity in older adults with metastatic castration-resistant prostate cancer (mCRPC) treated with androgen receptor targeted (ART) therapies. Journal Of Clinical Oncology 2023, 41: 117-117. DOI: 10.1200/jco.2023.41.6_suppl.117.Peer-Reviewed Original ResearchMetastatic castration-resistant prostate cancerPSA progression free survivalAdvanced prostate cancerProstate cancerSurvival outcomesBaseline characteristicsAndrogen receptorCastration-resistant prostate cancerProgression free survivalCompare survival outcomesCompare baseline characteristicsAge of diagnosisCox proportional hazards modelsProportional hazards modelMount Sinai HospitalFree survivalOverall survivalFischer's exactNo significant differenceMedical historyMultivariate analysisPrimary outcomeSecondary outcomesPost-chemoSide effectsClinical characteristics and outcomes of trial-ineligible patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving androgen receptor targeted (ART) therapy.
Mellgard G, Mccroskery S, Chakrani Z, Saffran N, Taylor N, Liaw B, Galsky M, Oh W, Tsao K, Patel V. Clinical characteristics and outcomes of trial-ineligible patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving androgen receptor targeted (ART) therapy. Journal Of Clinical Oncology 2023, 41: 118-118. DOI: 10.1200/jco.2023.41.6_suppl.118.Peer-Reviewed Original ResearchMetastatic castration-resistant prostate cancerPoor performance statusEligible ptsClinical trialsSurvival outcomesBaseline characteristicsMetastatic castration-resistant prostate cancer treated with abirateroneCastration-resistant prostate cancerCOU-AA-302Compare survival outcomesCOU-AA-301Trial-ineligible patientsCox proportional hazards modelsProportional hazards modelMedian OSPoor PSFischer's exactPerformance statusProstate cancerNo significant differenceTreatment startClinical characteristicsSignificant comorbiditiesAndrogen receptorPost-chemotherapy
2022
Transcriptomic profiling identifies genomic markers associated with benefit from stereotactic body radiation therapy (SBRT) in oligoprogressive metastatic renal cell carcinoma (mRCC).
Zengin Z, Govindarajan A, Muddasani R, Salgia N, Sayegh N, Tripathi N, Salgia S, Meza L, Zhang J, Chawla N, Chehrazi-Raffle A, Malhotra J, Dizman N, Hsu J, Castro D, Byron S, Dandapani S, Pal S. Transcriptomic profiling identifies genomic markers associated with benefit from stereotactic body radiation therapy (SBRT) in oligoprogressive metastatic renal cell carcinoma (mRCC). Journal Of Clinical Oncology 2022, 40: 4555-4555. DOI: 10.1200/jco.2022.40.16_suppl.4555.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaStereotactic body radiation therapySystemic treatmentSystemic therapyLess benefitCompletion of SBRTRole of SBRTHigh expressionBody radiation therapyRenal cell carcinomaT-testStudent's t-testHypoxia-related genesCommon histologyOligoprogressive diseaseClinicopathologic characteristicsMedian ageFischer's exactClinical benefitCell carcinomaClear cellsRadiation therapyTreatment durationTreatment changesIncreased expression
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply